Member Info for AquaeSulis01

I recall talk of Croda having 12000 clients, 12 of which were selected as VIPs hence the slip I suspect.
On the sales front, it is a pity that a comment regarding the unaudited figures for July and August mentioned by both TW and Elric and apparently showing a marked increase in Axis sales, was not included in the RNS. Using media influencers who are themselves psoriasis sufferers through a media such as Tiktoc would typically involve say a weekly update clip demonstrating whether axisbiotix is working for them. Depending on the speed of improvement it could well take a month or two before visible improvement is seen to be happening and hence acting as a catalyst for followers who are fellow sufferers to order the product for themselves. Here's hoping that is what is starting to filter through in the short term

So with the change in strategy away from D2C, does that mean Danielle Bekker who was brought in as non-exec director for her ecommerce, digital media and use of influencers, will be leaving the company?

Average order size I suspect (because of the 56 day time to optimally work and pricing discount for 2 months worth) represents two months at a time I suspect. There is now an 85% retention rate so 15% loss of new order customers each time which would give you 4 bi-monthly sales revenues approx the £75k; let's hope the marketing team have made an impact post June

Article also in the Times News Network on the other side of the pond

https://timesnewsnetwork.com/news/entertainment/everything-you-need-to-know-about-psoriasis-what-causes-it-what-makes-it-worse-and-the-best-creams-for-psoriasis/

This from the Business Update Sep 2020
"Bailieston Project - Blue Moon

Blue Moon is an exciting new gold discovery made by MGA, with intercepts from 2019 reverse circulation (RC) drilling including 15 metres at 3.81 g/t gold from 51 metres downhole (with 2 metres at 17.87 g/t gold) (see announcement dated 14 March 2019 for full details of the drill programme). The best 2019 drilling results came from the western fence line. The host sandstone thins towards the east, where the drill results diminished accordingly.

ECR plans to test whether the mineralisation continues to improve towards the west, subject to gaining surface access. There is also potential to carry out further drilling within the zones already tested, with the objective of establishing an initial JORC Mineral Resource."
And subsequently from the Aug 2022 update
"INITIAL DRILLING PROGRAM SEPTEMBER 2022

Drilling will be undertaken using ECR’s owned and operated diamond drill rig named ‘MIDAS’. Initial drillholes will be collared within the public track easement as shown in (fig 1). From these two locations, drilling will firstly investigate the possible strike extension of the Blue Moon prospect west of and at the point where the RC drill program in 2019 finished. Four initial holes are planned for an approximate total of 1000m, the outcome of which will determine further drilling. If the planned drilling successfully intersects mineralisation, this has potential to double the strike extent of the prospect.

NEXT STEPS

Previous drilling at Blue Moon only covered a small section of the outcrop. The deposit is open at depth and also along strike to the west and east. Permissions from landholders are currently in progress to explore the potential strike further to the east where an interpretative cross fault ends the known current outcrop. Plans are already in place to expand the drilling programme subject to results from the initial four holes."

So I suspect the reason for the Blue Moon delay is twofold; firstly to refine targets based on ECR's growing knowledge and confidence in the geological model to minimise cost and maximise chance of success, and they have had to wait for permissions from Landowners to extend the drilling programme further west

Nice plug for axisbiotix in the Glamour UK Magazine
https://www.glamourmagazine.co.uk/gallery/psoriasis-treatment

Nice piece written by Elric in the public domain giving a potted history of Skinbiotherapeutics for potential investors/new investors to the company
https://knowledge.sharescope.co.uk/2022/08/26/small-company-champion-the-human-biome-a-developing-health-frontier-part-2/

First, worth pointing out that the figures produced from the recent update are for the prebiotic side of the business only and that the probiotix side of the house run by Probiotix Health (where all LTH's and ex LTH's including me hold a dividend in specie) may well have fared a lot better.
SOH on the prebiotix side of the house faces a real dilemma for his first generation products. He has set up the business as a B2B entity with the online shop designed as a shop window for business rather than a D2C interface. His major prebiotic B2B partners H&B and THG in the UK and the Australian partners appear to have stocked up big to guard against supply chain issues at the end of last year and then subsequently struggled to shift end stock to a consumer market tightening their belts to spend on essentials with any discretionary spend going on long delayed holidays abroad. Belatedly he is now trying to move towards a D2C strategy in an adhoc fashion. but without appropriate marketing he is unlikely to reach any Customers outside the niche shareholder group and their immediate friends and family with repeat buys and if he does succeed in broadening the customer base, he is likely to alienate his current B2B partners if he starts competing in their territory in a serious fashion with an alternative product (i.e. Gofigure porridge v Slimexpert porridge). The probiotic side of the house (standfast the red yeast issue with cholbiome X3) appears to be in a better position to pursue the D2C route as they are not in direct competition with their major Customer Seed Health with their multi probiotic DS-01 product that is going from strength to strength and does not appear to be viewed as a discretionary purchase

H&B have over 1300 shops around the world, 750 of which are in the UK. They also accounted for 2/3rds of the Opti UK revenue the last time separate accounts were produced for Optibiotix Ltd in 2020 (prebiotic side of the business) representing £246,750 of the £369,892 revenue generated for the UK only. To be fair, the shops have never been packed and H&B does have a big online presence where big discounts are offered over the physical stores. If H&B survive as a business during these torrid retail times, then not unreasonable to expect to see a significant reorder appear in H2 accounts along with the annual royalty from the US sweetbiotix Partner and if there is the promised India launch will collectively show a big improvement on the lowly H1 figure of £122K. For info H1 Prebiotics Revenue for 2020 was £398,271 and this had risen to £539,819 by H1 2021, so has fallen a long way. Not a buy back in for me at the moment, but will watch for positive indicators as the year progresses (to include new batch end dates on the slim expert porridge to indicate a further H&B order has taken place)

elrico, wouldn't be the first time SOH has breached the lock in but accept it is unlikely at this point in time. Opti received £2.9M from skin share sells last year and had £2M in cash @ end 2021 as a result. The cash balance has now fallen by £0.5M to £1.5M end Jun 2022; fortunately cash burn is now split between Probiotix Health (where the IPO fund raise of £2,5M will tide them over), and Optibiotix Health)which will keep the lights on until the anticipated second half weighted revenue arrives from H&B and their Australian partner.

Beginning to wonder if SOH is selling down to keep the lights on at Opti after that shocking update today

Yes TW stuck is head in the sand re the discretionary nature of the products slimbiome is incorporated in despite flagging up the disretionary nature of a number of other products produced by certain other companies. Mentioned as I recall that SOH had informed him he wasn't compromising ingredient margins but obviously failed to mention the lack of orders maybe as a result. At least his sharestock event may have a late surge in attendance as folk await his "grilling" of SOH

I suspect it is largely down to "delayed" orders from H&B who are the main contributor to slimbiome revenue and lack of a follow-up order from THG for leanbiome after their bulk initial purchase at the end of last year. I regularly buy the slim expert range porridge from H&B and have already commented on the price discounts continually in operation in an attempt to stimulate sales of this and all their other discretionary products, and have noticed that all my purchases have a best before end date of Jan 2023. It may well be that H&B made a very large stock up order last year to guard against supply chain issues and are now just running down their stocks before re-ordering.

Bubs, totally agree with you. Whether they have or haven't been selling a few (for them) off to contribute towards dividend payments for their holders is irrelevant as the statement made in the link made it abundantly clear that they firmly believe in the future prospects of skinbiotherapeutics.

Bubs, yes it was also historic relating to the period up to 30th June but does show they are selling. Also worth bearing in mind the statement was for Seneca Growth Capital VCT only where 1,857,107 skin shares were held, Seneca Partners Ltd held 10,936,036 skin shares across all their portfolios at 30th Jun so possible other portfolios have sold down is it not?

belgrano, we know that Seneca have been reducing their holdings courtesy of the link provided by mol

Farris, Stuart has signed NDAs with Croda as is not free to RNS anything without their approval and we have been told Croda intend to launch via VIP clients and will wish to maximise the impact on the market on launch.
Regarding the Oral Health Study, if you read the further R&D getting underway in the link previously provided (extract below) there is every indication that the sort of barrier protection provided and adapted from the lysate, is exactly the right way to go and we have been told all is on track
"One important system affected by ageing, is our immune system, influencing our ability to both fight infection and maintain tolerance. This is a particular problem at barrier sites, interfaces between the internal body and the external world (such as the gut and oral cavity). The immune system at these sites has to mediate a delicate balance; it must protect against pathogen entry and also be able to distinguish these bad invaders from commensal/friendly bacteria. This is a difficult challenge and to achieve this the immune system is carefully tailored to barrier sites creating highly specialized networks of immune cells that enforce this balance and ensure the integrity of barrier sites. Maintaining this balance becomes increasingly difficult with advancing age.

Although age-driven changes in immune function have been assessed in the gut, the influence of age on the immune network present at the oral barrier remains minimally explored. This is a significant oversight given that advancing age is accompanied by loss of oral barrier integrity and an increased incidence and severity of oral inflammation. Moreover, recent data has shown that oral inflammation is a risk factor for a plethora of disorders associated with unhealthy aging, including cardiovascular disease and diabetes. As such it becomes increasingly important to understand the age-associated changes occurring at the oral barrier.

The objectives of this grant are to determine the functional changes to oral barrier immune responses with age and to define the oral-specific factors that educate the oral barrier immune network across a life-time. By employing novel techniques that I have developed alongside cutting edge-technology, this work will transform our understanding of tissue-specific control of immune homeostasis at the oral barrier throughout a healthy life-time. In particular this work will assess the factors that promote immune dys-regulation at the oral barrier and undermine barrier homeostasis with age."

Nice short technical explanation of the upcoming drilling

Power Metal Resources (@PowerMetRes) · Twitter

See that Marshall Wace increased its short again on the 19th Aug

And the your refers to SO H not you of course :)